Kerala-based research institute develops tiny sensor for early Parkinson’s detection

Scientists in Kerala-based research institute have achieved a major milestone in medical science by creating a microscopic, self-assembling sensor capable of detecting early warning signs of brain disorders like Parkinson’s.

The breakthrough, published online in the prestigious journal Nature Nanotechnology recently, was led by researchers at the BRIC-Rajiv Gandhi Centre for Biotechnology (RGCB) based in Thiruvananthapuram. Led by PhD student Varsha Shaji and postdoctoral researcher Dr Neethu Puthumadathil under the supervision of Dr Kozhinjampara R. Mahendran, the team designed synthetic "nanopores"—molecular tunnels so tiny that they can scan individual disease-related proteins one by one.

The Hunt for Invisible Killers

To understand why this is a big deal, we have to look at how diseases like Parkinson’s and Amyotrophic Lateral Sclerosis (ALS, a motor neurone disease) behave inside our bodies. These conditions are linked to specific proteins that misbehave. Instead of doing their normal jobs, these proteins warp into irregular shapes and clump together like sticky hairballs in the brain.

Spotting these changing proteins is incredibly difficult. They exist in tiny amounts in our blood. Conventional blood tests simply cannot "see" them easily because they change their shapes constantly. For doctors trying to diagnose patients early, it is like trying to identify individual vehicles on a highway from a satellite photo. Scientists have long needed a highly sensitive, adjustable scanner to catch these proteins in action.

A Smart Trap Made of Proteins

This is where the Thiruvananthapuram team stepped in. Instead of building a rigid metal machine, they used nature’s own building blocks. They took a single biological peptide—which is simply a short chain of amino acids, the basic ingredients of proteins—and modified it.

They engineered this peptide so that when it is put into an artificial lipid membrane, it automatically fits together like puzzle pieces to form tiny tunnels. Remarkably, this single ingredient can form two different-sized tunnels, which the team named "S" (small) and "L" (large) pores. This dual-pore design is a major breakthrough in nanopore engineering. By tweaking the structure using unnatural amino acids, the researchers could precisely control the size of the tunnels to screen different molecules.

Catching Parkinson’s Clumps in the Act

How does it work? When a tiny electrical current is passed through these pores, ions flow through them. When a disease protein enters the tunnel, it blocks the flow of electricity. Because every protein has a unique size and electric charge, each one blocks the current in a distinct way—leaving a unique electrical "fingerprint".

Using the larger "L" pores, the researchers successfully detected different versions of a protein called alpha-synuclein, which is highly linked to Parkinson’s disease. The pore was so sensitive that it caught these proteins at extremely low, nanomolar concentrations. More importantly, it allowed the team to watch the clumping process in real time. They tracked how harmless single proteins slowly merged into toxic clumps and eventually long fibers. They even tested a green tea compound called EGCG, showing how it successfully reroutes and stops this toxic clumping.

Meanwhile, the smaller "S" pores were used to detect humanin—a peptide linked to cell death—and SOD1, a protein associated with the debilitating disease ALS.

What Lies Ahead

This invention does not just mean better diagnostics; it provides a laboratory platform to test new medicines. Drug developers can now watch under the molecular microscope to see if their new formulations can stop toxic proteins from clumping together.

Looking ahead, the RGCB team hopes to refine their design so these programmable nanopores can work reliably under normal physiological conditions. They also want to create highly stable, artificial pores using unnatural amino acids that can survive inside living cells, opening up new doors for delivering medicines directly to diseased areas.